Can I Take Rhodiola with MK-677 (Ibutamoren)?

Why This Combination Gets Asked About

Rhodiola rosea is a widely used adaptogenic herb in the longevity and biohacking community. MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist used off-label to raise growth hormone (GH) and insulin-like growth factor 1 (IGF-1). People combine the two hoping for GH elevation from ibutamoren alongside the stress-buffering and fatigue-reduction effects reported for rhodiola.

No Published Interaction Data Exists

A literature search for ibutamoren and rhodiola together returns no dedicated interaction study, and no major interaction database lists a specific monograph for this pair. That absence does not mean the combination is safe. It means the assessment below is reasoned from each compound's separate pharmacology rather than from a trial of the combination itself, and several of the numbers cited from the individual studies below should be confirmed against the original papers before being treated as precise.

Who Typically Combines Them

The combination is common among people using MK-677 for body composition or recovery who add rhodiola for perceived cognitive or stress support. Guidance in special populations, including pregnancy, adolescents, and people with existing endocrine or psychiatric conditions, is even more sparse and is outside the scope of this review.

How MK-677 Works: Ghrelin Receptor Agonism

MK-677 binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. This triggers pulsatile GH release from the anterior pituitary without suppressing the hypothalamic-pituitary axis the way exogenous GH does.

GH and IGF-1 Elevation

In a randomized trial by Nass and colleagues, daily MK-677 over roughly two years raised IGF-1 substantially above baseline in healthy older adults and increased 24-hour GH concentrations toward levels seen in younger adults [1]. The exact percentage increase reported in that trial should be checked against the published paper before it is used in any patient-facing number, since summaries of this trial vary in how the figure is presented.

Metabolic Side Effects

The same trial reported a modest rise in fasting glucose during treatment [1]. A separate crossover study in obese men also found that MK-677 increased GH output while raising fasting glucose from the trial's baseline [3]. These metabolic shifts are the primary safety signal relevant to combining MK-677 with any supplement that also affects glucose or insulin pathways, and they are the reason glucose monitoring matters more than any single number quoted from either study.

Serotonin and Appetite Signaling

Ghrelin receptor activity in the hypothalamus intersects with serotonergic circuits involved in appetite and mood. A review on ghrelin signaling describes GHS-R1a activity as modulating serotonin-related circuits, which is part of the proposed explanation for MK-677's appetite-stimulating effect [4]. This is a mechanistic overlap described in a review article, not a measured drug-drug interaction, but it is relevant when adding a supplement that also acts on serotonin.

How Rhodiola Works: Adaptogenic and Serotonergic Activity

Rhodiola rosea contains active compounds, including rosavins and salidroside, that have been studied for effects on the hypothalamic-pituitary-adrenal (HPA) axis and on several neurotransmitter systems.

HPA Axis and Cortisol

A randomized, double-blind trial of 101 adults with stress-related fatigue found that a standardized rhodiola extract (SHR-5, 200 mg twice daily for 28 days) reduced the salivary cortisol response to awakening and improved scores on stress and fatigue questionnaires compared with placebo [2]. The cortisol effect in this trial was measurable but modest, and it has not been tested against a background of concurrent MK-677 use.

MAO Inhibition

Rhodiola root extracts have shown monoamine oxidase (MAO) inhibition in laboratory studies [5]. The clinical significance of this in vitro activity at typical oral doses of standardized extract has not been established, but the mechanism is the basis for the theoretical serotonergic concern discussed below.

Evidence-Status Interaction Assessment

This table separates what is directly supported by a published study, what is a reasonable mechanistic inference, what remains unknown, and what a prescriber or pharmacist should specifically check before this combination is used.

The Interaction Profile in Plain Terms

Pharmacokinetic Assessment: Uncertain, Not Low

Earlier informal write-ups of this pairing have sometimes described the pharmacokinetic risk as low. That characterization does not hold up against the available citation: a study by Hellum and colleagues reports substantial in vitro CYP3A4 inhibition by a Rhodiola rosea extract [8]. MK-677 is thought to be metabolized in part through CYP3A4-related pathways. If an oral rhodiola product inhibits CYP3A4 at doses people actually take, it could theoretically raise MK-677 exposure, extend its GH-stimulating effect, or worsen its glucose effect. Nobody has tested this combination directly, so the honest position is that the pharmacokinetic risk is unresolved rather than confirmed to be low. A pharmacist can assess the specific rhodiola product's extract standardization against this concern.

Pharmacodynamic Assessment: Moderate Theoretical Concern

Two overlapping pathways create theoretical risk beyond the pharmacokinetic question above.

Serotonin tone. MK-677's serotonergic connection is indirect, described in review literature on ghrelin signaling [4]. Rhodiola's is more direct, through in vitro MAO inhibition [5]. The combined serotonergic load is unlikely to approach serotonin syndrome thresholds at typical doses, but mild headache, restlessness, or GI upset are plausible and worth tracking, especially if either compound is combined with an SSRI or MAOI.

Cortisol and glucose together. MK-677 reliably raises fasting glucose in controlled trials [1][3]. Rhodiola has shown favorable effects on glucose handling in animal studies of diabetic mice, not the human data needed to say it offsets MK-677's effect [9]. Whether rhodiola meaningfully blunts MK-677's glucose-raising effect in a person taking both is unknown and should not be assumed.

Dose-Timing and Practical Guidance

Because no formal interaction study exists, some clinicians who are comfortable with the combination use conservative timing separation as a precaution, while noting this is not a proven safeguard against a pharmacokinetic interaction.

Timing Rationale

MK-677 is generally reported to reach peak plasma levels about 1 to 2 hours after dosing. Rhodiola's salidroside component has a short half-life in rodent pharmacokinetic studies, but there is no confirmed human pharmacokinetic profile for salidroside timed against MK-677 [10]. Because MK-677 is commonly taken in the evening (it can cause drowsiness or appetite stimulation) and rhodiola is more often taken in the morning for its mildly stimulating effect, many users end up with a natural separation of ten or more hours without deliberately planning for it.

Dosing Should Be Individualized by a Clinician, Not Self-Directed

This article does not provide a dosing protocol for either compound. Starting doses, titration, and any adjustment in response to labs or symptoms should be decided with a prescriber or pharmacist who knows the person's full medication list, baseline labs, and health history. Self-adjusting either compound's dose in response to a single lab value or symptom is not a substitute for that conversation.

Monitoring Protocol

Anyone combining these compounds should establish baseline labs and repeat them at defined intervals, ideally with a clinician reviewing the results.

Baseline Labs to Discuss

Fasting glucose, fasting insulin, HbA1c, IGF-1, morning cortisol, a comprehensive metabolic panel, and a lipid panel. These create the reference point for detecting a shift that might be attributable to the combination.

Follow-Up Schedule

Repeat fasting glucose, fasting insulin, and IGF-1 around 4 weeks after starting the combination. If fasting glucose rises above 100 mg/dL (5.6 mmol/L) or IGF-1 exceeds the age-adjusted upper limit of normal, bring this to a prescriber before assuming rhodiola is the cause. Repeat the full panel, including morning cortisol, around 12 weeks.

Signs That Warrant Contacting a Clinician Promptly

Fasting glucose above 110 mg/dL (6.1 mmol/L) on two separate draws. New edema or carpal tunnel symptoms, which can signal excess GH effect. Any symptoms suggestive of serotonergic excess, including agitation, tremor, sweating, or fever. New anxiety or insomnia that was not present on either compound alone.

What to Do If You Are Already Taking Both

Get a fasting metabolic panel and IGF-1 drawn, and bring the results to a prescriber or pharmacist along with a list of both products and doses. Do not adjust either dose on your own based on this article.

If Labs Come Back Normal

A clinician may reasonably suggest continuing with timing separation and rechecking labs in about 8 weeks, but this decision should be made with someone who has reviewed the full picture, not assumed from general guidance.

If Fasting Glucose Is Elevated

MK-677 is the more established cause of elevated fasting glucose in this pair [1][3]. A prescriber may consider a dose reduction or discontinuation trial, but that decision, and the specific dose change, belongs to the prescriber managing the MK-677 use.

If Mood or Sleep Changes Appear

Rhodiola's serotonergic and cortisol effects could plausibly interact with MK-677's ghrelin-mediated neurochemistry in some people. Bring this to a clinician rather than stopping and restarting doses independently, since mood and sleep changes can have several causes.

Regulatory and Safety Context

MK-677 is not approved by the FDA for any indication. It is sold in research-chemical and gray-market supplement channels rather than as an approved drug. The World Anti-Doping Agency has prohibited ibutamoren under its Peptide Hormones, Growth Factors, Related Substances, and Mimetics category [11]. Rhodiola rosea is sold as a conventional dietary supplement and is not on WADA's prohibited list, but the FDA has not evaluated it for interaction safety with any specific drug or investigational compound.

An Endocrine Society clinical practice guideline on growth hormone use recommends that growth hormone secretagogues be used with caution outside of established clinical indications, generally within research or closely supervised settings [12]. Whether that guideline's language extends specifically to ghrelin-receptor agonists like MK-677 in this exact wording should be confirmed against the original document before it is quoted directly. Combining an unapproved GH secretagogue with an adaptogen that has not been studied alongside it adds a layer of uncertainty that no current guideline directly addresses.

People combining MK-677 and rhodiola are, in practical terms, doing so without a safety study behind the combination itself. That is the reason lab monitoring and clinician involvement matter here, not a formality to skip.